About Icons

Icon	Function
💬	A pop-up explanation appears when you mouse-over the text beside this icon. Also, an explanation window appears when you click this icon.
	The links beside this icon are links to external sites.
	Clicking this icon sorts the table by the item with this icon (Numerical or alphabetical order). Each click toggles between ascending and descending order.
	A text longer than 100 characters is fully displayed or collapsed.
	The contents of the displayed table are downloaded as a file named "table.csv".

Drug Description in Trials / DrugBank / KEGG DRUG

Search results

No.

Drug (Description in trials)

DrugBank

KEGG DRUG

KEGG GENES

KEGG PATHWAY

Disease ID

1

Bezafibrate
(D01366)

[1] Bezafibrate

[1] Bezafibrate (D01366) 💬

[1] NR1C1 💬

[10] Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬

[8] 20, 93, 94, 160, 296, 316, 324, 344 💬

Disease ID	Name
20	Adrenoleukodystrophy
93	Primary biliary cholangitis
94	Primary sclerosing cholangitis
160	Congenital ichthyosis
296	Biliary atresia
316	Carnitine cycle disorder
324	Methylglutaconic aciduria
344	Very long-chain acyl-CoA dehydrogenase deficiency

2

Bezafibrate (400MG) IN addition TO standard 15-20 MG/KG/jour udca therapy
(D01366)

[2] Bezafibrate,
Ursodeoxycholic acid

[2] Ursodiol ,
Bezafibrate (D01366) 💬

[2] NR1C1,
NR1H4 💬

[11] Adipocytokine signaling pathway, Alcoholic liver disease, Bile secretion, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬

[1] 94 💬

3

Bezafibrate 100 MG
(D01366)

[1] Bezafibrate

[1] Bezafibrate (D01366) 💬

[1] NR1C1 💬

[10] Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬

[1] 93 💬

4

Bezafibrate 200 MG
(D01366)

[1] Bezafibrate

[1] Bezafibrate (D01366) 💬

[1] NR1C1 💬

[10] Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬

[1] 93 💬

5

Bezafibrate 200 MG IN addition TO udca therapy
(D01366)

[2] Bezafibrate,
Ursodeoxycholic acid

[2] Ursodiol ,
Bezafibrate (D01366) 💬

[2] NR1C1,
NR1H4 💬

[11] Adipocytokine signaling pathway, Alcoholic liver disease, Bile secretion, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬

[1] 93 💬

6

Bezafibrate 200 MG oral tablet
(D01366)

[1] Bezafibrate

[1] Bezafibrate (D01366) 💬

[1] NR1C1 💬

[10] Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬

[1] 93 💬

7

Bezafibrate 400 MG
(D01366)

[1] Bezafibrate

[1] Bezafibrate (D01366) 💬

[1] NR1C1 💬

[10] Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬

[1] 93 💬

8

Bezafibrate 400 MG IN addition TO udca therapy
(D01366)

[2] Bezafibrate,
Ursodeoxycholic acid

[2] Ursodiol ,
Bezafibrate (D01366) 💬

[2] NR1C1,
NR1H4 💬

[11] Adipocytokine signaling pathway, Alcoholic liver disease, Bile secretion, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬

[1] 93 💬

9

Bezafibrate IR
(D01366)

[1] Bezafibrate

[1] Bezafibrate (D01366) 💬

[1] NR1C1 💬

[10] Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬

[1] 93 💬

10

Bezafibrate SR
(D01366)

[1] Bezafibrate

[1] Bezafibrate (D01366) 💬

[1] NR1C1 💬

[10] Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬

[1] 93 💬

11

Bezafibrate, beza, BZF, bezalip
(D01366)

[1] Bezafibrate

[1] Bezafibrate (D01366) 💬

[1] NR1C1 💬

[10] Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬

[1] 93 💬

12

Bezafibrate, beza, BZF, bezalip mono
(D01366)

[1] Bezafibrate

[1] Bezafibrate (D01366) 💬

[1] NR1C1 💬

[10] Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬

[1] 93 💬